Aktieanalys

2cureX: Launches Its Third IndiTreat Test - Redeye

{newsItem.title}

Redeye Publicerad: 14 Mar 2022 10:39

Redeye endorses 2cureX launching its third test, IndiTreat Explore, and thereby completing its portfolio rollout plan for 2022. We continue to see good prospects for 2cureX going forward and reiterate our Base Case.

Länk till analysen i sin helhet: https://www.redeye.se/research/836233/2curex-launches-its-third-inditreat-test?utm_source=finwire&utm_medium=RSS

Nyheter om 2cureX

Läses av andra just nu

Om aktien 2cureX

Senaste nytt